Functional Skills

M&A Support
Market Research
Financial Modeling
Valuation
Industry Expertise
Competitive Landscaping
Growth Strategy
Business Intelligence

Software Skills

Microsoft Excel
Microsoft Office
Microsoft Word
Microsoft PowerPoint
Salesforce
Sharepoint
Sage Intacct
Outlook

Sector Experience

Financial Services
Healthcare
Life Sciences & Pharma
Technology

Languages

Korean
Portuguese
English

Experience

Independent Consulting Corporate Strategy & Development
Consultant
1/2022 - Present
Advise early-stage healthcare companies focus on market and category definition, competitive dynamics, growth, and ultimately sustainable profitability

Develop decentralized clinical trials (DCT) strategy within R&D Data Science of a Fortune 100 pharmaceutical company

DST Systems Corporate Strategy & Development
VP Healthcare Strategy
7/2015 - 2/2020
Led Healthcare Services segment strategic planning process and facilitated the implementation of high- profile, high-impact projects end-to-end, from developing an approach to delivering recommendations and final deliverables; oversaw broader communications on strategic direction, execution and performance tracking.

Conducted industry, market, competitor, and financial analyses, including operating and valuation models for acquisitions, partnerships and joint ventures.

Blue Cross Blue Shield of Kansas City Corporate Strategy & Development
Strategy Consultant
12/2012 - 12/2014
As the senior member of the strategy & analytics team, developed high visibility and impact enterprise strategy; identified new business opportunities; worked with senior leadership to gain approval and buy-in for major initiatives that are consistent with the organization’s long-term goals and objectives; made recommendations on course(s) of action and allocation of resources.

Led enterprise-wide efforts as the subject matter expert in the establishment of a market landscape framework.

Independent Consulting Corporate Strategy & Development
Consultant
5/2010 - 10/2012
Developed an international growth strategy for a biopharmaceutical company and led market segmentation and share analysis effort for the distribution of an $8-million orphan drug.

Conducted commercial due diligence – including off-label indication pricing studies for a nascent $130-million rare disease market – to support the client’s market expansion plans and pricing decisions via a thorough review and analysis of the competitive and reimbursement environments.

Deutsche Bank Asset Management Finance
Equity Research Analyst
3/1998 - 4/2009
Oversaw generics and European brand pharmaceuticals and health care services (managed care, facilities, distributors, retail pharmacies, and PBMs) investment positioning across the firm’s global active equity platform; served as the in-house subject matter expert on health care related legislative and regulatory policies and their potential impact to portfolio positions.

Conducted in-depth fundamental research – identifying quality, mispriced companies with long-term investment horizons.